Viviani S, Mazzocchi A, Pavoni C, et al. - Given that the prognostic value of PET done after the first two treatment cycles (PET‐2) in patients with advanced‐stage classical Hodgkin lymphoma receiving ABVD chemotherapy has been reported, and considering that 15% of patients with a negative PET‐2 will encounter treatment failure, researchers prospectively assessed serum thymus and activation‐regulated chemokine (TARC) concentrations, to improve risk evaluation among patients managed according to HD0607 PET‐driven trial. Serum TARC levels were evaluated, at baseline as well as at time of PET‐2, in 266 patients with available serum samples, who consented to engage in a sub‐study for evaluation of the role of TARC monitoring. To determine the link between TARC following 2 ABVD cycles and PFS was the primary endpoint. PET‐2‐positive patients vs PET‐2‐negative patients as well as patients with treatment failure vs those in continuous CR were found to have significantly higher median TARC‐2 values. A significant difference in 4‐year PFS was evident between patients with TARC‐2 > 800 pg/mL vs ≤800 pg/mL. Study's findings showed that TARC‐2 serum levels above 800 pg/mL suggest the requirement for a stringent follow‐up in PET‐2‐negative patients, and the assessment of novel drugs in PET‐2‐positive, who will probably fail to respond to intensification with escalated BEACOPP.